Idiopathic pulmonary fibrosis: now a treatable disease and other highlights from the 2014 American Thoracic Society Annual Conference

ATS 2014 photo

by Matthew Stanbrook, Deputy Editor, CMAJ, in San Diego, U.S.A.

Idiopathic pulmonary fibrosis is a chronic progressive disease in which the normal connective tissue of the lungs (the interstitium) is replaced by scar tissue through mechanisms we are rapidly understanding much better. The disease causes the lungs to become stiff (decreased lung compliance), small (lung restriction) and impaired in their primary function of gas exchange (impaired diffusion capacity). It affects an estimated 20,000-30,000 Canadians and has a median survival of 2-4 years from diagnosis, although some patients live much longer. While its onset is typically late in life, the disease can rarely occur much earlier, as attested by my hospital’s lung transplantation program, whose graduates include triumphs like social media superstar and Ellen DeGeneres guest Hélène Campbell, as well as tragedies like Cambridge, Ontario’s organ donation advocate Kayla Baker, who despite getting a new lung died earlier this year at the tender age of 15. I have had the privilege of crossing paths with both of these young women, whose stories are inspiring, yet serve as a stark reminder of the desperate need for effective treatments for this disease.

Patients with idiopathic pulmonary fibrosis, and those of us who care for them, have long been frustrated by the lack of such treatments, and more so by the fact that most innovative therapies tested to date have failed to show benefit and have often increased rather than decreased mortality. All this has suddenly changed with new research presented last week at the 2014 American Thoracic Society Annual Conference. These studies have now documented clear and compelling benefits of two medications, one of which is already in clinical use in Canada. Another equally important study has shown the lack of benefit of an older but widely used treatment.

Let’s start with the bad news. For decades, we had been treating idiopathic pulmonary fibrosis with potent systemic anti-inflammatory medications such as prednisone, azathioprine, and cyclophosphamide, based on the observation that chronic inflammation is a consistent feature of the disease, but likely the wrong mechanism on which to focus, as it turns out. We did so well in advance of obtaining any good evidence of benefit with this approach, which as usual turns out to have been a bad idea. In 2011, the large PANTHER IPF trial, evaluating combination therapy with prednisone, azathioprine and acetylcysteine, was stopped early by its data safety monitoring board due to findings of increased mortality with this regimen. In addition to a placebo arm, this trial had a 3rd arm that was randomized to acetylcysteine alone. After a brief hiatus of 3 months, the PANTHER IPF trial was allowed to continue with these latter 2 arms.

Acetylcysteine (also referred to as N-acetylcysteine or NAC) was thought to be possibly beneficial in idiopathic pulmonary fibrosis based mainly on the IFIGENIA study, which in 2005 showed that patients randomized to acetylcysteine, prednisone and azathioprine had less of a decline in vital capacity (a validated surrogate outcome measure in idiopathic pulmonary fibrosis) than those randomized to prednisone and azathioprine alone. Tellingly, IFINGENIA did not have an arm that was untreated, and in retrospect it seems more likely that acetylcysteine may have decreased the tendency for prednisone and azathioprine to kill patients, although given PANTHER IPF’s initial findings, clearly not well enough. Acetylcysteine’s purported beneficial mechanism lay in its property as the biological precursor of glutathione, which functions in the lung as a major antioxidant. That should have been a red flag right there—more often than not, “antioxidant properties” seems to be scientific code for “we really have no idea how this treatment would actually work” and denotes a treatment that turns out not to once proper studies are done. The final results of the PANTHER IPF trial, presented at the conference by Ganesh Raghu, Professor and Director of the Interstitial Lung Disease/Sarcoid/Pulmonary Fibrosis Program at the University of Washington, proves that acetylcysteine doesn’t work, either: there was no difference between patients receiving acetylcysteine or placebo in vital capacity (the primary outcome), death, or other clinical or surrogate endpoints that might denote benefit. There was an excess of non-fatal cardiac events in the acetycysteine group—of unclear meaning given the large number of outcomes evaluated, but certainly not encouraging.

As respirologist and New England Journal of Medicine Editor-in-Chief Jeffrey Drazen stated at the conference, there was never a good scientific reason to think that acetylcysteine alone would work in idiopathic pulmonary fibrosis; instead, “this was a straw at which people grasped”. Unfortunately, it seems a few are still grasping: while most of the IPFnet investigators were balanced and appropriate in describing the trial results, PANTHER IPF investigator and Executive Vice Chair of Medicine at Weill Cornell University Fernando Martinez devoted much of a separate session at the conference to highlighting observed differences in “trends” between patients enrolled before and after the 2011 alert that temporarily halted the trial—notwithstanding that none of the differences reached statistical significance. This is specious and unscientific. As PANTHER IPF investigator and Chair of Medicine at the University of California, San Francisco, Talmadge King—arguably the world’s leading authority on interstitial lung diseases—stated, “I don’t know how you make a big deal over something meaning nothing”. Right you are, Dr. King. Acetylcysteine has fallen into common use, in part because it can be widely obtained without prescription as a supplement, and perhaps because it is thought at least to be harmless (which, as it turns out, may not be the case). We all need to move on and to encourage our patients to move on as well, not to waste their money and their hope on a treatment that doesn’t work.

And we finally have an effective therapy towards which to move: pirfenidone. Pirfenidone was previously tested in the 2 large CAPACITY randomized trials. Unfortunately, only 1 of the 2 trials showed a significant difference in the primary outcome, vital capacity. This was good enough to get the drug approved for clinical use in Canada and Europe, but not good enough for the U.S. Food and Drug Administration, which refused to approve the drug and mandated a new study. The results of this study, the ASCEND trial, were present at the conference by Dr. King. Unlike its predecessors, the ASCEND trial featured greater attention to quality control, with centralized adjudication of pulmonary function measurements and clinical events. I have been skeptical of pirfenidone to date, given the past track record of treatment for idiopathic pulmonary fibrosis that I described above, and also because we still don’t know the mechanisms by which this treatment acts in IPF (remembering the example of acetylcysteine). However, the results of ASCEND seem quite convincing: the proportion of patients who died or experienced a significant decline in vital capacity after 1 year was lower in the pirfenidone group by an absolute difference of 15% (equivalent to a number needed to treat of 7). When the results of ASCEND were pooled with those of the two CAPACITY trials, the findings were homogeneous and revealed a statistically significant 48% reduction in the hazard of all-cause mortality and a two-thirds reduction in mortality attributed specifically to pulmonary fibrosis.

In addition to pirfenidone, we will soon have a second therapy with demonstrated efficacy in idiopathic pulmonary fibrosis: nintedanib. Unlike pirfenidone, we actually know how this one works: it’s a tyrosine kinase inhibitor, a class of medications that has spawned several new anti-cancer drugs recently. Its mechanism, as helpfully explained at the conference by Martin Kolb, Associate Professor of Respirology, Pathology and Molecular Medicine at McMaster University, is that, as with all tyrosine kinase inhibitors, it mimics ATP and thereby prevents cellular signaling from the cell membrane to the nucleus. Of specific relevance here, nintedanib does so in fibroblasts, inhibiting their migration, proliferation and transformation to myofibroblasts—all key steps in the pathogenesis of idiopathic pulmonary fibrosis, which best resembles a misdirected process of wound healing and repair. Nintedanib has now been evaluated in the paired INPULSIS-1 and INPULSIS-2 trials, presented at the conference by Luca Richeldi, Professor of Respiratory Medicine and Chair of Interstitial Lung Disease at the University of Southhampton, UK. As with pirfendione, nintedanib showed a clinically and statistically significant different in vital capacity at 1 year. Deaths were also fewer with nintedanib, although differences did not reach statistical significance (the trials were not powered to evaluated mortality).

These new findings have immediately sparked much well-justified optimism within the respiratory community. For the first time, we can now confidently regard idiopathic pulmonary fibrosis as a treatable disease. There remain many substantial hurdles to overcome for our patients: as Dr. Drazen pointed out, these drugs have shown they can slow the progression of disease, but in most cases haven’t stopped it. There is thus immediate interest in studying these drugs in combination with each other and with other promising agents in development that have been derived from an improved understanding of disease mechanisms (such as simtuzumab, an inhibitor of lysyl oxidase like-2, an enzyme whose activity has been implicated in the formation of fibroblast foci, which are a pathologic hallmark of idiopathic pulmonary fibrosis). Both drugs have common side effects, particularly involving the GI tract, although these seem tolerable in severity. And both, of course, will be expensive. However, with clear benefits and a mortality reduction now documented for a frequently fatal disease that has previously had no clearly effective treatments, regulatory authorities, insurance companies and government third-party payers will have a hard time saying no.

Of course, there was more than idiopathic pulmonary fibrosis on display at the conference. Other research highlights included:

  • Among women who continued to smoke during pregnancy, infants of mothers who were randomized to Vitamin C 500 mg per day had better lung function at birth and fewer episodes of wheeze at 1 year than those whose mothers were randomized to placebo and similar in both respects to infants of non-smoking mothers. Benefits were seen predominantly with mothers who carried a known nicotinic receptor polymorphism previously shown to be associated with smoking-related lung diseases. Noteworthy for being one of the few randomized trials to show that Vitamin C does anything worthwhile in anyone, but the biological rationale appears to have been much better worked out in this case and lends plausibility to the findings. Of course, the most important and effective treatment in this context is smoking cessation, but the evidence that the mechanism of neonatal lung impairment may be based on effects of nicotine would imply that pregnant women using nicotine replacement therapy for this purpose should perhaps also receive Vitamin C.
  • E-cigarette vapour increased the virulence of methicillin-resistant Staphylococcus aureus (MRSA) in a mouse model. This was similar to the effect of cigarette smoke, although the mechanisms were different. The results provide more evidence suggesting that e-cigarettes are not a harmless substitute for cigarette smoking.
  • Statins do not reduce COPD exacerbations, it seems. In the STATCOPE trial, a unique collaboration funded by both the Canadian Institutes of Health Research and the U.S. National Heart, Lung and Blood Institute, simvastatin 40 mg daily, given for 1-3 years to COPD patients who did not otherwise have an indication for a statin, showed no obvious benefits or harms. Similarly, in the RODEO trial, rosuvastatin 10 mg daily for 12 weeks did not improve pulmonary or peripheral artery endothelial function. These studies thus fail to confirm prior observational data suggesting that statins might be beneficial in COPD. Oh, and it seems that statins are of no benefit in ARDS associated with sepsis, either.
  • Lung volume reduction for COPD, attempted endoscopically with a gelfoam sealant, more than doubled the risk of respiratory adverse events, including 2 deaths, leading to the premature termination of the ASPIRE trial. Conventional lung volume reduction performed surgically has been shown previously to be of potential benefit, but only in a small proportion of highly selected COPD patients. Hopes that this therapy might be expanded to more patients with less invasive approaches continue to meet with frustration—even if the idea is sound, the right technique just isn’t there yet, it seems.
  • Vitamin D supplementation in asthma patients who were Vitamin D deficient did not reduce asthma treatment failure or facilitate dose reduction of inhaled steroids, even though it did usually raise Vitamin D levels above the threshold for sufficiency. The hypothesis was based on prior studies suggesting that Vitamin D deficiency is associated with worse asthma outcomes. Vitamin D deficiency has been implicated in the pathogenesis of several diseases in which Vitamin D supplementation has subsequently failed to demonstrated benefit. Perhaps asthma should now be counted among these, although in fairness, the VIDA trial really shows only that Vitamin D cannot replace an effective dose of inhaled steroids, rather than ruling out any potential benefit of Vitamin D in asthma.

24 thoughts on “Idiopathic pulmonary fibrosis: now a treatable disease and other highlights from the 2014 American Thoracic Society Annual Conference

  1. Neville MORAY

    I am 79 years old. Two years ago I noticed that I was finding it harder to walk in the hills, but since I was overweight and taking beta-blockers which prevented heart acceleration, my doctors told me to lose weight and exercise more. After two two years y condition suddenly worsened, and following an xray and a MRI scan I was diagnosed with IPF. I was able to start taking a corticosteroid and Pirfenidone last March, and the progress of the disease has almost halted. I am still very breathless if I climb the 15 steps to our front door, but I was able to swim using a slow crawl for at least 300 metres a day all summer, and I can walk for 1.5 km in about 30 minutes on a slight incline. My cough has greatly declined and is present only when tired in the evening. Even then it is slight and can be managed by relaxing and breathing slowly. I have come off beta blockers but am still having a calcium channel blocker. I had a double coronary bypass about 25 years ago.
    Pirfenidone seems very effective.

    Neville Moray.

  2. This is really encouraging to hear. Especially Neville's experience with the new IPF treatments. My grandfather has pulmonary fibrosis. He is not yet on the meds but has been considering it. The biggest problem for him is shortness of breath and weight loss. I understand the drugs may not reverse that, but at least it could maybe plateau things for awhile. There's another site that has been very helpful in educating my family on these issues. It's written by an MD and has lot's of good daily living tips for IPF patients. Here's the link if you know someone who might find this helpful:

    1. George F

      I had a bad situation with the Ejiro Herbal Clinic. I sent them $100.00 for the herbs and found out after that they wanted over $100.00 to ship them. I said no way and they refused to refund me my money. I do not recommend using them.

  3. Joan

    I was diagnosed of Pulonary fibrosis in March 2014, my doctor told me it has no permanent cure, i was given medication to ease the situation, this affected me so badly as i constantly go short of breath, this continued till a friend of mine Karen told me about Ejiro Herbal Clinic were she bought herbal medicine that totally cured her mother of pulmonary firbosis, I contacted this herbal clinic via their email and purchasd the pulomnary fibrosis herbal remedy, i received the herbal medicine within 7 days and when i started usage my lungs gradually got better until i even forgot i had pulmonary fibrosis, i went back to my familly doctor to test for idiopathic pulmonary fibrosis my doctor confirmed my lungs tissue were 98% repaired.

    1. Patricia Blasi

      Hi Joan,
      I read your July 27, 2016 blog about being cured of pulmonary fibrosis with herbs from Ejiro Herbal
      where is it and any other relevant info?
      Thank you

    2. Ameer

      Dear Sir,
      My father is also suffering from ipf and his lungs has shrink almost 46% . Dr recommended to be on oxygen concentrator for 24 hours and pirfenix is not slowing the progression of the disease. Can you please advise me any natural herbal remedy in order to try and stop the disease.
      Thanks in advance

      Looking forward to hear from you soon.

    3. Alvin

      My dad also suffers from pulmonary fibrosis and we badly need help in finding a cure for him... Can you please send me details on how we can get the herbs?

    4. Susan Trevino

      Thank you Joan, Four years ago I experienced a severe breathing and wheezing problem that my doctor diagnosed as chronic bronchitis with dust allergy. A year later, it worsened and I was diagnosed of COPD. I came across Herbal HealthPoint [ww w. herbalhealthpoint. c om] December, 2018 and learnt about their successful herbal therapy for COPD. I immediately started on the COPD treatment; few weeks into the treatment, i began to notice a reduction in symptoms till it all vanished. I feel better and breath better. I Just wanted to share for people suffering from this horrible lungs disease.

  4. G Fales

    When are we gong to see some treatment for COPD/Emphazema? Everything seems to be about pulmonary fibrosis. I am glad to see there is a treatment fvor this, however, what is research doing for COPD?

  5. The True Janey Sue

    Please do not buy into "Joan's" story of her supposed cure. I've found from other reputable sites that it is a total scam. Not to mention, there is no way that scarred tissue will reverse itself in the lungs. Damage will not get better. The disease may slow in its progression, but anyone who states it will repair damage already done is not being truthful. Please do not send money to anyone who promises a miracle cure. You will make a scammer richer and you will be poorer.

  6. Im Simone Bever i was diagnosed of Pulmonary Fibrosis for 4 years, i have tried several doctors with different types of medications with no help, i was browsing the net and i came across Standard Herbs Home i decided to give a try and i purchased their herbal remedy and i used it for 3 weeks and i am totally cure of Pulmonary fibrosis. Thanks to you Standard Herbs Home.

  7. Lynn Wathall

    After my 3rd pulmonary embolism in 2003, I was diagnosed with pulmonary fibrosis and I read that people usually die within 5 years. My specialist has me on blood thinners, prednisone and other steroids that I inhale daily. October 2006 I decided to go with natural treatment and was introduced to Green House Herbal Clinic natural organic idiopathic pulmonary fibrosis Herbal formula, i had a total decline of symptoms with this pulmonary fibrosis Herbal formula treatment. The infections, shortness of breath, fatigue, dry cough and other symptoms has subsided. Somehow, the herbs managed to keep me alive for 13 years.Visit Green House Herbal Clinic official website I have had great improvement with my over all respiration with this product and i breath very much easier, i can never be thankful enough to nature

    1. Debra

      Hi Lynn, my dad was just diagnosed with IPF! I'm so upset! I feel so depressed . Can you send me info on all that you did to achieve such great results.
      I'm so very happy for you! God bless

    2. Linda Costa

      Lynn. I was just diagnosed. Don’t know what to try. Can you please tell me what you have been taking. Many blessings to you. Thank you. Linda Costa

  8. Levi Jasper

    I am 59 now. I was diagnosed with COPD in March of 2013. I had been a heavy smoker, got a cold I couldn't get rid of, ended up in the hospital, on a ventilator. I should have known it was coming, but like most smokers, thought it would never happen to me. I don't smoke now and never will again, but, I still want to. My life has changed drastically. I had to stop working, sold my home (couldn't afford it without a salary),the COPD disease has kept down since diagnosed if not for the herbal formula of Total cure herbal foundation i would have been in hospital with the use oxygen managing my condition,total cure herbal foundation finally get rid of my disease with their natural herbal products in just 14 weeks of usage which i have been on other medication for ages but am really glad now that my lungs has return to it normal position.
    contact: Totalcureherbalfoundation@ gmail. com

  9. Fred Gilbert

    A CT scan in August of 2009 verified that I had Idiopathic Pulmonary Fibrosis. My first symptoms were cough and shortness of breath. I was on prednisone and inhalers. My blood oxygen level was 50 and i was extremely short of breath, i was barely able to breath. I went through cardio pulmonary rehab, It helped but not too long before all the severe symptoms returned. December last year, a family friend told us about Rich Herbs Foundation and their successful lungs disease treatments, we visited their website ww w. richherbsfoundation. c om and ordered their IPF herbal treatment, i am happy to report this treatment effectively reversed my Idiopathic pulmonary fibrosis and symptoms. I am back on my feet, i walk daily now and has made me able to walk my two dogs again without shortness of breath or sudden loss of energy. My activity level is up again.

  10. Judy Winder

    Hi everyone i had ASTHMA my whole life but about 7 years ago my asthma got so bad and was diagnosed of EMPHYSEMA/COPD which was most likely due to the asthma. I was on double antibiotics and steroids, still didn't feel any better. My lungs were constantly wheezing in all four chambers, i already used Advair, Spiriva, and Albuterol in my nebulizer, they just didn’t do much. It was hell for me due to the difficulty in  breathing. My sister in-law told us about herbal health remedies foundation where he ordered herbs that effectively treated her arthritis. We ordered their COPD TREATMENT after reading a-lot of positive reviews from other patients, i am happy to report the COPD TREATMENT was very effective for my lungs condition, every one of my symptoms including difficulty breathing, respiratory infections, chronic cough and wheezing has simply stopped. I will be 52 soon and have never been better like this before after using their herbs and am grateful for the help they have done for me thank Herbal Health Remedies Foundation.

  11. Zack Colton

    I had chronic obstructive pulmonary disease (COPD) for 7 years. My first symptoms were dry cough, chest tightness and shortness of breath. My first chest x-ray only showed bronchitis. Finally I went to a pulmonologist and was diagnosed with COPD,i never thought i could get rid of this lung disease not until I found their supplement are 100% guaranteed.

  12. beckym

    I have been diagnosed of COPD for years now, i have used so many prescriptions from my doctor but never gave me a cure or improvement rather controlling the symptoms, my health and life was gradually deteriorating more and more, so i took a glance on the internet and i found (GENERAL HEALTH CENTER) a HERBAL MEDICINE HOME that thier remedy for COPD works, i gave a test to their herbal product because there is no harm in trying, i bought the medicine and it was shipped to my doorstep and i was very happy so i used the herbal medicine (note: this is a herbal remedy) i used this herbal medicine for 4 weeks the results were wonderful, i started getting good result, my symptoms was gradually going away, i started getting healed, i can feel that because i know how i was before i started using the herbal medicine, and in 4 weeks ,my improvements was good and totally permanent.. thanks to general health center.
    contact them today via email address: generalhealthcenter1 @ gmail .com or whatsapp +27715655936 ....................


Leave a Reply

Your email address will not be published. Required fields are marked *